NeuroScientific Biopharmaceuticals (ASX:NSB) has announced that it has commenced the transfer of its patented manufacturing process for its mesenchymal stromal cells from Cell and Tissue Therapy (Royal Perth Hospital) to Q-Gen Cell Therapeutics (Q-Gen) of QIMR Berghofer Medical Research Institute (QIMR Berghofer).
The company said its subsidiary, Isopogen Australia Opco, had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen would undertake manufacturing process development, scale-up and clinical grade manufacture of its proprietary StemSmart platform technology.
Q-Gen, located within QIMR Berghofer in Brisbane, is one of the largest cell therapy contract manufacturers in Australia, with 13 cleanrooms dedicated to cell manufacturing and quality control. Q-Gen specialises in manufacturing cellular immunotherapies for clinical trials.
NeuroScientific said the commencement of the technology transfer to Q-Gen is a critical milestone to establish its cell manufacturing and enable it to undertake further clinical trials and pursue commercial opportunities.
CEO Nathan Smith said, “We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the Company to scale the manufacturing of its StemSmartTM technology to address substantial market opportunities.”
QIMR Berghofer's Dr Stephen Weller added, “QIMR Berghofer is delighted that NeuroScientific Biopharmaceuticals has selected the Q-Gen Cell Therapeutics facility to manufacture their GMP cell therapy. Q-Gen’s commitment to advancing cell therapies means we look forward to a long-term partnership with the Isopogen team and bringing their StemSmartTM technology to the clinic to improve the lives of chronically ill patients.”